Global clinical research organization boosts its capability to build studies in-house and make mid- BARCELONA, Spain – 9 Nov. 2022 \u2014<\/strong> Veeva Systems<\/a> (NYSE: VEEV) today announced Excelya<\/a> is using Vault EDC<\/a> for electronic data capture (EDC)<\/a>, data cleaning, and reporting in clinical trials. The full-service contract research organization (CRO) will benefit from faster database build cycles and zero downtime when making mid-study design amendments.<\/p>\n \u201cVeeva\u2019s innovative technology and services have transformed our approach to managing complex clinical trials,\u201d said G\u00e9raldine Mercier, global head of data management at Excelya. \u201cOur study teams appreciate how Veeva Vault EDC\u2019s drag-and-drop functionality and agile user acceptance testing make study design quick and simple.\u201d <\/p>\n Excelya is an independent, global CRO offering fully integrated design and execution of phase I to IV clinical trials to pharmaceutical, biotechnology, and medical device companies. By optimizing clinical data capture with Vault EDC, Excelya now has a system in place to accelerate the design and execution of high-quality trials. Excelya is also leveraging Veeva RTSM<\/a> for full randomization and trial supply management, integrated with Vault EDC to further streamline data workflows.<\/p>\n \u201cEffective data capture is key to running successful clinical trials,\u201d said Paul MacDonald, senior director of strategy, Veeva Vault CDMS. \u201cExcelya\u2019s addition of Veeva Vault EDC is an important step in transforming its approach to data management by simplifying study builds and trial execution for faster development of new medicines.\u201d<\/p>\n Additional Information<\/strong><\/br> About Excelya <\/strong> For more information, visit www.excelya.com<\/a> About Veeva Systems<\/strong> Veeva Forward-looking Statements<\/strong> ###<\/p>\n
study amendments faster<\/em><\/p>\n
\nFor more on Veeva Vault EDC, visit: veeva.com\/eu\/VaultEDC <\/a>
\nConnect with Veeva on LinkedIn: linkedin.com\/company\/veeva-systems<\/a>
\nFollow @veeva_eu on Twitter: twitter.com\/veeva_eu<\/a>
\n<\/p>\n
\nExcelya is an independent contract research organization, headquartered in Europe with 900 employees across 25 countries globally. Excelya offers pharmaceutical, biotechnology, medical devices companies all cooperation models, from resourcing to functional service provision to full-service solutions. As a fully integrated CRO, Excelya undertakes the design and execution of clinical trials from phase I to IV. Excelya is committed to providing preeminent experts who work hand-in-hand with its clients to accelerate end-to-end drug development, leverage data science and reimagine patient care.<\/p>\n
\nConnect with Excelya on LinkedIn: Excelya<\/a><\/p>\n
\nVeeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world\u2019s largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com\/eu<\/a>.<\/p>\n
\nThis release contains forward-looking statements regarding Veeva\u2019s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended July 31, 2022, which you can find here<\/a> (a summary of risks which may impact our business can be found on pages 39 and 40), and in our subsequent SEC filings, which you can access at sec.gov<\/a>.<\/p>\n